



Rising Contagious Diseases

**Basics, Management,
and Treatments**

Edited by
Seth Kwabena Amponsah
Ranjita Shegokar
Yashwant V. Pathak

WILEY

Rising Contagious Diseases

Rising Contagious Diseases

Basics, Management, and Treatments

Edited by

*Seth Kwabena Amponsah
Department of Medical Pharmacology
University of Ghana Medical School
Accra, Ghana*

*Ranjita Shegokar
Chief Scientific Officer (CSO)
Capnomed GmbH, Germany*

and

*Yashwant V. Pathak
USF Health Taneja College of Pharmacy
University of South Florida
Tampa FL, USA*

and

*Faculty of Pharmacy
Airlangga University
Surabaya, Indonesia*

WILEY

Copyright © 2024 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.

Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data

Names: Amponsah, Seth Kwabena, editor. | Shegokar, Ranjita, editor. | Pathak, Yashwant, editor.

Title: Rising contagious diseases : basics, management, and treatments / edited by Seth Kwabena Amponsah, Ranjita Shegokar and Yashwant V. Pathak.

Description: Hoboken, New Jersey : Wiley, [2024] | Includes bibliographical references and index.

Identifiers: LCCN 2023039506 (print) | LCCN 2023039507 (ebook) | ISBN 9781394188710 (cloth) | ISBN 9781394188727 (adobe pdf) | ISBN 9781394188734 (epub)

Subjects: MESH: Communicable Diseases, Emerging--prevention & control | Communicable Disease Control--trends

Classification: LCC RA566 (print) | LCC RA566 (ebook) | NLM WA 110 | DDC 616.9/8--dc23/eng/20231211

LC record available at <https://lcn.loc.gov/2023039506>

LC ebook record available at <https://lcn.loc.gov/2023039507>

Cover Design: Wiley

Cover Image: © Baac3nes/Getty Images

Set in 9.5/12.5pt STIXTwoText by Straive, Pondicherry, India

Dedication

This book is dedicated to all health workers who continuously work hard to save the lives of many people with infectious diseases. Thank you for your dedication, commitment, and courage. Deepest gratitude and admiration to all scientists who have made contributions toward getting a better understanding of infectious pathogens and also to researchers who work tirelessly to develop new drugs and vaccines.

Additionally, this book is dedicated to all the rishis, sages, shamans, and medicine men and women of ancient traditions and cultures who have contributed to the development of drugs and nutraceuticals. They have kept health science alive for the past several millennia.

Contents

List of Contributors	xxxv
Foreword	xxxi
Preface	xxxii
Biographies	xxxiii
1 Emerging and Re-Emerging Infectious Diseases of the Decade: An Overview	1
<i>Ranjita Shegokar, Seth K. Amponsah, and Yashwant V. Pathak</i>	
1.1	Introduction 1
1.2	Infectious Diseases and the Economy 1
1.3	The Main Factors Involved in EIDs and REIDs 2
1.4	Prevention of EIDs and REIDs 3
1.5	Infectious Diseases of the Last Decades 4
1.5.1	Middle East Respiratory Syndrome (MERS) 4
1.5.2	Severe Acute Respiratory Syndrome (SARS) 5
1.5.3	COVID-19 5
1.5.4	Dengue 5
1.5.5	Ebola 5
1.5.6	Influenza 5
1.5.7	Viral Hepatitis 5
1.5.8	Mpox 5
1.5.9	Zika Virus 5
1.5.10	Swine Flu 6
1.6	Conclusion 6
	References 6
2 Recent Trends and Possible Future Trajectory of COVID-19	7
<i>Ismaila Adams, Ofosua Adi-Dako, Eugene Bofo, Emmanuel K. Ofori, and Seth K. Amponsah</i>	
2.1	Introduction 7
2.2	Overview of COVID-19 8
2.2.1	Summary of Timelines and Major Events 8
2.2.2	Key Characteristics of SARS-CoV-2 8
2.2.3	Transmission Modes of SARS-CoV-2 9
2.2.3.1	Close Contact Transmission 9
2.2.3.2	Airborne Transmission 9
2.2.3.3	Fomite Transmission 9
2.2.3.4	Other Possible Transmission Routes 10
2.3	Current State of the Pandemic 10
2.3.1	Global and Regional Trends in COVID-19 Cases, Hospitalizations, and Deaths 10
2.3.2	Variants of Concern and Their Impact on Transmission and Severity 10
2.3.3	Pharmacotherapy of COVID-19 10

2.3.4	Vaccination	10
2.4	Epidemiological Projections and Modeling	11
2.4.1	Different Models Used to Predict Future Trajectory of COVID-19	11
2.4.2	Factors Influencing the Projections	12
2.4.3	Uncertainties and Limitations Associated with Modeling Approaches	12
2.5	Potential Scenarios for the Future	12
2.5.1	Presentation of Multiple Scenarios Based on Different Assumptions and Variables	12
2.5.2	Examination of Best-Case, Worst-Case, and Most Likely Scenarios	12
2.5.3	Factors That Could Influence the Trajectory	13
2.6	Impact of COVID-19 on Public Health and Healthcare Systems	13
2.6.1	Analysis of the Potential Burden of COVID-19 on Healthcare Systems in Different Scenarios	13
2.6.2	Addressing Potential Challenges of COVID-19 on Healthcare	13
2.6.3	Impact of COVID-19 on Non-COVID Healthcare Services and Long-Term Healthcare Planning	14
2.7	Socioeconomic and Behavioral Considerations	14
2.7.1	Analysis of the Socioeconomic Impact of the Pandemic and Potential Future Outcomes	14
2.7.2	Behavioral Changes and Their Long-Term Implications	14
2.7.3	Exploration of Societal Responses and Adaptive Measures	14
2.8	Global Preparedness and Response	15
2.8.1	Lessons Learned from the Pandemic and Their Application to Future Outbreaks	15
2.8.2	Global Cooperation and Preparedness Efforts	15
2.8.3	Exploration of the Role of Technology and Innovation in Pandemic Response	15
2.9	Conclusion and Recommendations	16
2.9.1	Recommendations for Policymakers, Public Health Officials, and Researchers	16
2.9.2	Identification of Areas for Further Research and Study	16
	References	17

3 Mpox: New Challenges with the Disease 20

Julia Wang, Lynn Nguyen, Vernon Volante, Jeannez Daniel, and Charles Preuss

3.1	History of Mpox virus	20
3.2	Characteristics	20
3.3	Epidemiology	20
3.4	Transmission	21
3.5	Pathogenicity	22
3.6	Risk Factors	23
3.7	Diagnostic Testing	24
3.8	Symptoms	24
3.9	Long-Term Effects and Complications	25
3.10	Vaccinations	26
3.11	Epidemic Management	27
3.12	Pharmacology	28
3.13	Future Implications	29
3.14	Conclusion	29
	References	29

4 Ebola Virus Disease: Transmission Dynamics and Management 31

Kshama Patel, Jasmine Primus, Carina Copley, and Yashwant V. Pathak

4.1	Introduction	31
4.1.1	Origins of Ebola Virus	31
4.1.2	Symptoms	32
4.1.3	Risk Factors	32
4.1.4	Diagnosis	32
4.2	Transmission Dynamics	33

4.2.1	Human to Human Transmission	33
4.2.2	Different Outbreaks	33
4.3	Disease Management	34
4.3.1	Prevention	34
4.3.1.1	Proper Hygiene and Avoiding Contact	34
4.3.1.2	Medicinal Prevention Methods	34
4.3.2	Medical Treatments	34
4.3.2.1	Inmazed	35
4.3.2.2	Ebanga	35
4.3.2.3	Limitations to Treatments	35
4.3.3	Experimental Therapies	36
4.3.3.1	ZMapp and Remdesivir	36
4.4	Morbidity	36
4.4.1	Short-Term Symptoms	36
4.4.2	Convalescence	37
4.5	Intersections	37
4.5.1	Socioeconomic Status	38
4.5.2	Social Stigma	38
4.5.3	Cultural and Traditional Practices	39
4.6	Conclusion	39
	References	39

5 Avian Influenza Outbreaks over the Last Decade: An Analytical Review and Containment Strategies 42

Abdullah Abdelkawi, Zaineb Zinoune, Aliyah Slim, and Yashwant V. Pathak

5.1	Background	42
5.1.1	Emergence and Spread of Avian Influenza (2013–2023)	42
5.2	Causative Microorganisms	43
5.2.1	H7N9 and H5N8 (2013–2023)	43
5.2.2	H5N1: Impact on Humans	43
5.2.3	H7N9: Impact on Humans	44
5.2.4	H5N8: Impact on Humans	44
5.2.5	H5N1: Impact on Animals	44
5.2.6	H7N9 and H5N8: Impact on Animals	45
5.3	Strategies for Containment	45
5.4	Ongoing Investigations and Prospective Look into Avian Influenza	46
	References	47

6 Swine Flu: Current Status and Challenges 50

Lucy Mohapatra, Geeta Patel, Alok S. Tripathi, Alka, Deepak Mishra, Sambit K. Parida, Mohammad Yasir, and Rahul K. Maurya

6.1	Introduction	50
6.2	Current Status – Swine Flu	51
6.2.1	Swine Influenza Viruses in Asia	51
6.2.2	Swine Influenza Virus in Other Continents	52
6.2.3	Human to Swine IAV Transfer – Two-Way Transmission	53
6.3	Pathogenesis Related to Swine Flu	53
6.3.1	Symptoms Related to Swine Flu	53
6.3.2	Pathological Changes During Swine Flu	53
6.3.3	Pathogenesis and Host Response in Swine	55
6.4	Diagnosis	55
6.4.1	Histopathology	56
6.4.2	Pig Selection	56

6.4.3	Serology	56
6.4.4	Virus Characterization	56
6.4.5	Oral Fluids	56
6.5	Treatment and Management of Swine Flu	57
6.5.1	Vaccination Against Influenza in Swine	57
6.5.1.1	Currently Available Vaccine for Swine Flu	57
6.5.1.2	Experimental Vaccine for Swine Flu	57
6.5.2	Modern Therapeutic Approach	57
6.5.3	Traditional Approaches for the Therapeutic Interventions of Swine Flu	58
6.6	Challenges During Combating Swine Flu	58
6.6.1	Challenge to Control Swine Influenza	58
6.6.2	Challenge for Livestock and Human Health	60
6.7	Conclusion	60
	References	60

7 Zika Virus Disease: An Emerging Global Threat 66

Ofosua Adi-Dako, Awo A. Kwapong, and Selorme Adukpo

7.1	Introduction	66
7.2	Epidemiology of the Zika Virus Infection	66
7.3	Infection and Pathophysiology	67
7.4	Immune Response and Vaccine	68
7.5	Zika Virus Infection Diagnosis and Management	69
7.6	Development of Antiviral Therapeutic Drug against Zika Virus	69
7.7	The Way Forward	70
	References	70

8 Current Perspectives in Dengue Hemorrhagic Fever 72

Manish P. Patel, Vaishnavi M. Oza, Hemangi B. Tanna, Avinash D. Khadela, Praful D. Bharadia, and Jayvadan K. Patel

8.1	Introduction	72
8.2	Life Cycle of Dengue Mosquitoes	74
8.3	Life Cycle of Dengue Virus	74
8.4	Risk Factors Responsible for Dengue Fever	75
8.5	Pathophysiology of Dengue Fever	75
8.5.1	The Viral Genome	75
8.5.2	Structure and Function of the NS Proteins	76
8.5.3	Dengue Symptoms	76
8.6	Clinical Manifestation	76
8.6.1	Febrile Phase	76
8.6.2	Critical/Leakage Phase (Early Detection of Plasma Leakage/Shock)	77
8.6.3	Recovery/Convalescent Phase	78
8.7	Diagnosis of Dengue Fever	78
8.8	Prevention of Disease	80
8.8.1	Vaccine	80
8.8.2	Prevent Mosquito Bites	80
8.8.3	Reduce Mosquito Habitat	81
8.8.4	Case Surveillance and Vector Surveillance	81
8.8.5	Community-Based Control Programs	81
8.8.6	Biological Control	82
8.8.7	Chemical Control	82
8.9	Management of Dengue Disease	83
8.9.1	Hydration	83
8.9.2	Ancillary Therapeutic Modalities	84

8.9.3	Management of Volume Overload	84
8.9.4	Decrease Ammonia Production	85
8.10	Conclusion	85
	References	86
9	West Nile Virus: Evolutionary Dynamics, Advances in Diagnostics, and Therapeutic Interventions	87
	<i>Bibhuti B. Kakoti, Lawandashisha Nongrang, Chinmoyee Borah, Monali Lahiri, Mainak Ghosh, and Ankit Choudhary</i>	
9.1	Introduction	87
9.2	Geographical Distribution	88
9.3	The Virus and its Genome	89
9.3.1	Phylogeny	89
9.4	Etiology and Pathogenesis	90
9.4.1	The Transmission of the West Nile Virus Within the Mosquito Host	90
9.4.2	Proliferation, Viral Multiplication, Dissemination, and the Initial Infection	90
9.4.3	Neuroinvasion	92
9.5	Relationship Between Host-Pathogen in West Nile Virus Infection	92
9.6	Clinical Presentation of West Nile Virus	93
9.6.1	West Nile Fever (WNF)	94
9.6.2	West Nile Neuroinvasive Disease	94
9.6.2.1	West Nile Meningitis (WNM)	94
9.6.2.2	West Nile Encephalitis (WNE)	94
9.6.2.3	West Nile Poliomyelitis (WNP) and Acute Flaccid Paralysis (AFP)	95
9.7	Management of West Nile Virus	95
9.7.1	Polyclonal Immune Globulin Intravenous (IGIV)	95
9.7.2	Polyclonal IGIV with High Titers of WNV Antibodies Derived from Blood Donors (Omr-IgG-Am)	96
9.7.3	WNV Recombinant Humanized Monoclonal Antibody (MGAWN1)	96
9.8	Recent Advancements in Diagnostics, Clinical Assessment, and Treatment	96
9.8.1	Diagnosis and Clinical Assessment	96
9.8.2	Treatment	97
9.9	Conclusion and Future Prediction	98
	References	99
10	Hantavirus Disease: A Global Update over the Last Decade	106
	<i>Anita Patel, Nisarg Patel, and Jayvadan K. Patel</i>	
10.1	Introduction	106
10.2	Life Cycle	106
10.2.1	Genome Organization and Virion Structure	107
10.3	Ecology and Evolution of Hantavirus	108
10.3.1	Rodent Reservoirs of Old World Hantaviruses	108
10.3.2	Rodent Reservoirs of New World Hantaviruses	109
10.3.3	Evolution of Hantaviruses	110
10.4	Epidemiology of Hantavirus Infections	111
10.4.1	Epidemiology of Old World Hantaviruses	111
10.4.2	Epidemiology of New World Hantaviruses	112
10.5	The Clinical Course of Hantavirus Diseases and Pathology	113
10.5.1	European and Asian HFRS Disease Spectrum	113
10.5.2	Spectrum of HPS Disease in the Americas	113
10.5.3	Pathogenesis	114
10.6	Laboratory Diagnosis of Hantavirus Infection	114
10.6.1	Serologic Diagnosis	115
10.6.2	Enzyme-Linked Immunosorbent Assay	115

10.6.3	Immunofluorescence Assay	115
10.6.4	Immunoblot Assay	115
10.6.5	Focus Reduction Neutralization Test	115
10.6.6	Molecular Detection of Hantaviruses	116
10.7	Treatment and Prevention	116
10.7.1	Treatment	116
10.7.2	Ribavirin	116
10.7.3	Favipiravir	117
10.7.4	Lactoferrin	117
10.7.5	Vandetanib	117
10.7.6	Immunotherapy	117
10.7.7	ETAR	118
10.7.8	Corticosteroids	118
10.7.9	Prevention	118
10.7.10	First-Generation Vaccines	118
10.7.10.1	Chinese and Korean Immunizations against the Inactivated HFRS	118
10.7.11	Second-Generation Vaccines	119
10.7.11.1	Virus-like Particle Vaccine	119
10.7.11.2	Recombinant Proteins	119
10.7.12	Third-Generation Vaccines	120
10.7.12.1	Recombinant Vector Vaccine	120
10.7.12.2	Nucleic Acid-Based Molecular Vaccine	120
10.8	Recent Outbreaks of Hantavirus	121
10.9	Summary and Conclusion	122
	References	122

11 Current Advances in Marburg Virus Disease 129

Emmanuel K. Ofori and Eric N.Y. Nyarko

11.1	Introduction	129
11.1.1	General Properties of Marburg Virus (MARV)	129
11.1.1.1	Classification and Taxonomy	129
11.1.1.2	Genetics, Molecular, and Chemical Composition with Their Characteristics	129
11.1.1.3	Etiology	131
11.1.1.4	Evolution	131
11.1.2	Laboratory Characteristics of the MARV	132
11.1.2.1	Cultivation and Detection of MARV	132
11.1.2.2	Reaction of MARV to Chemical and Physical Agents	132
11.1.2.3	Laboratory Safety of MARV	132
11.1.3	Mode of Transmission, Replication, and Intracellular Life Cycle	132
11.1.3.1	Mode of Transmission	132
11.1.3.2	Cellular Life Cycle and Replication of MARV	133
11.2	Pathogenesis and Pathophysiology of MARV	134
11.3	Marburg Virus Disease (MVD)	135
11.3.1	Historical Epidemiology of MVD	135
11.3.2	Immunity, Clinical Features, and Findings in MVD	137
11.3.2.1	Immune Evasion Mechanism of MARV	137
11.3.2.2	Clinical Features and Findings in MVD	138
11.3.3	Laboratory Diagnosis of MVD	138
11.3.4	Treatment, Control, and Prevention of MVD	139
11.3.4.1	Treatment	139
11.3.4.2	Control and Prevention	141
11.4	Conclusion	142
	References	142

12 Recent Advances in Combating Nipah Virus Disease 145*Mehul Chorawala, Aanshi Pandya, Ishika Shah, Bhupendra G. Prajapati, Nirjari Kothari, and Aayushi Shah*

- 12.1 Introduction 145
 - 12.1.1 Virus Structure and Biology 146
 - 12.1.2 Transmission 146
 - 12.1.3 Epidemiology 146
 - 12.1.4 Immunopathological Mystery of Nipah Virus Disease 148
 - 12.1.4.1 Innate Immunity and Interferon Type I Signaling 148
 - 12.1.4.2 Adaptive Immunity 149
 - 12.1.4.3 In Humans 150
 - 12.1.4.4 In Animals 150
 - 12.1.5 Clinical Presentation 151
- 12.2 Recent Advancements in Nipah Virus Diagnostic Tools 151
 - 12.2.1 Serological Methods 151
 - 12.2.2 Molecular Method 152
 - 12.2.3 Tissue-Culture Method 152
- 12.3 Recent Development in Therapeutics and Treatment Modalities Against NiV Disease 152
 - 12.3.1 Antivirals 153
 - 12.3.1.1 Ribavirin 153
 - 12.3.1.2 Favipiravir 153
 - 12.3.1.3 Remdesivir 156
 - 12.3.1.4 Acyclovir 156
 - 12.3.1.5 4'azidocytidine (R1479) 156
 - 12.3.1.6 4'-Chloromethyl-2'-Deoxy-2'-Fluorocytidine (ALS-8112) 156
 - 12.3.2 Monoclonal Antibodies 156
 - 12.3.2.1 m102.4 156
 - 12.3.2.2 h5B3.1 156
 - 12.3.3 Vaccines 157
 - 12.3.3.1 Subunit Vaccines 157
 - 12.3.3.2 Vector-Based Vaccines 157
 - 12.3.3.3 Virus-Like Particles (VLPs) 157
- 12.4 Conclusion and Future Directions 158
 - Acknowledgment 158
 - References 158

13 Middle East Respiratory Syndrome (MERS) 164*Orhan E. Arslan*

- 13.1 Introduction 164
- 13.2 Discussion 165
 - 13.2.1 Epidemiology 165
 - 13.2.2 Disease Development 167
 - 13.2.3 Pathogen Transmission 168
 - 13.2.4 Immune Response to Pathogen 168
 - 13.2.5 Clinical Signs and Symptoms 169
 - 13.2.6 Laboratory and Radiological Findings 170
 - 13.2.7 Pathological Findings 170
 - 13.2.8 Zoonotic Infection 170
 - 13.2.9 Diagnostic Methodologies 172
 - 13.2.10 Vaccination 172
 - 13.2.11 Therapeutic Regimen 172
 - 13.2.12 MERS-COV Animal Models 173
 - 13.2.13 Infection Control 173
- 13.3 Conclusions 174
 - References 174

14 Chikungunya Fever: Epidemiology, Clinical Manifestation, and Management 181*Chandrakanta, Bhupendra G. Prajapati, and Archana N. Sah*

- 14.1 Introduction 181
- 14.1.1 Structure 181
- 14.1.2 Target Cell 182
- 14.1.3 Transmission 182
- 14.1.4 Replication 182
- 14.1.5 Sign and Symptoms of CHIKF 182
- 14.1.6 Acute Phase Symptoms 182
- 14.1.7 Chronic Phase Symptoms 184
- 14.2 Epidemiology 184
- 14.2.1 Worldwide 184
- 14.2.2 In India 185
- 14.3 Clinical Manifestation 186
- 14.3.1 Rheumatic Manifestation 186
- 14.3.2 Ophthalmic Manifestation 186
- 14.3.3 Renal Manifestation 188
- 14.3.4 Dermatological Manifestation 188
- 14.3.5 Neurological Manifestation 188
- 14.3.6 Cardiovascular Manifestation 188
- 14.4 Diagnosis of Chikungunya Fever 189
- 14.4.1 Virus Isolation 189
- 14.4.2 Serology 190
- 14.4.3 Reverse Transcriptase Polymerase Chain Reaction 190
- 14.5 Management of Chikungunya Fever 190
- 14.5.1 For Acute Phase 190
- 14.5.1.1 First-Line Treatment 190
- 14.5.1.2 Second Line Treatment 190
- 14.5.2 For Subacute and Chronic Phase 190
- 14.5.2.1 Corticosteroids 190
- 14.6 Disease Modifying Antirheumatic Drugs 191
- 14.6.1 Chloroquine 191
- 14.6.2 Sulfasalazine 191
- 14.6.3 Methotrexate 191
- 14.7 Non-Pharmacological Treatment 191
- 14.8 Medicinal Plants for CHIKV and Its Associated Symptoms 191
- 14.8.1 *Persicaria odorata* 191
- 14.8.2 *Picrorhiza kurroa* 192
- 14.8.3 *Andrographis paniculata* 192
- 14.8.4 *Ipomoea aquatica* 192
- 14.8.5 *Azadirachta indica* 192
- 14.8.6 *Terminalia chebulla* 192
- 14.8.7 *Alpinia officinarum* 192
- 14.8.8 *Zingiber officinalis* 192
- 14.8.9 *Pisidium guajava* 193
- 14.9 Future Prospectives 193
- 14.10 Conclusion 193
- References 193

15 Lassa Fever: Recent Clinical Reports and Management Update 199*Abigail Aning, Kwasi A. Bugyei, Bismarck A. Hottor, and Seth K. Amponsah*

- 15.1 Background 199
- 15.2 Geographical Distribution 199

15.3	Mode of Transmission	199
15.4	Reservoir Hosts	199
15.5	Incidence and Prevalence	200
15.6	Clinical Presentation	200
15.7	Diagnostic Methods	201
15.7.1	Serological Assays	201
15.7.2	Polymerase Chain Reaction (PCR)	201
15.7.3	Imaging Techniques	201
15.8	Recent Clinical Reports	201
15.9	Management and Treatment	202
15.9.1	Antiviral Therapy	202
15.9.2	Supportive Care	202
15.9.3	Experimental Therapies	202
15.9.4	Immune-Based Therapies	202
15.10	Future Prospects and Research Directions	203
15.10.1	Vaccine Development	203
15.10.2	Therapeutic Interventions	203
15.10.3	Improved Diagnostic Tools	203
15.10.4	Strengthening Surveillance	203
15.10.5	Understanding Viral Pathogenesis	203
15.10.6	Public Health Interventions	204
15.10.7	One Health Approach	204
15.11	Conclusions	204
	References	204
16	Lyme Disease Management: Antibiotics and Beyond	207
	<i>Aparoop Das, Kalyani Pathak, Manash P. Pathak, Urvashree Gogoi, and Riya Saikia</i>	
16.1	Introduction to Lyme Disease	207
16.2	Modes of Transmission	208
16.3	Recent Trends in Lyme Disease Management	209
16.3.1	Significance of Early Detection	209
16.3.2	The Role of Education and Awareness	209
16.3.3	Non-Pharmacologic Approaches	209
16.3.3.1	Lifestyle Changes and Self-Care	209
16.3.3.2	Complementary and Alternative Therapies	210
16.3.3.3	Pharmacologic Management	210
16.3.4	Novel Approaches to Lyme Disease Treatment	212
16.3.4.1	Vaccination	212
16.3.4.2	Other Emerging Therapies	213
16.4	Future Directions and Challenges in Lyme Disease Management	214
16.5	Conclusion	215
	References	215
17	Chagas Disease: Historical and Current Trends	220
	<i>Vivek Patel, Dhara Patel, Grishma Patel, and Jayvadan K. Patel</i>	
17.1	Introduction	220
17.2	Discovery of Chagas Disease	221
17.3	Etiology of Chagas Disease	222
17.4	Lifecycle of <i>T. cruzi</i>	222
17.5	Clinical Forms of Chagas Disease	223
17.6	Diagnosis and Management of Chagas Disease	224
17.6.1	Treatment of Chagas Disease	226

- 17.6.2 Diagnosis, Management, and Treatment of Chronic Chagas Cardiomyopathy (CCC) and Gastrointestinal Complication 227
- 17.6.3 Public Health Initiatives, Local and International Associations, Awareness Campaigns, Regulatory Health Perspectives, and Chagas Disease Control Programmes 231
- 17.7 Conclusion 231
- References 232

18 Legionnaires' Disease: Current Trends in Microbiology and Pharmacology 237

Julia Wang, Neha Chintapally, Meera Nagpal, Anjali Mahapatra, and Charles Preuss

- 18.1 History of *Legionella* spp. 237
- 18.1.1 Characteristics 237
- 18.1.2 Epidemiology 238
- 18.2 Bacterial Life Cycle 238
- 18.3 Pathogenicity 238
- 18.4 Alterations to Host Cell Pathways 239
- 18.5 Ubiquitin Pathways 240
- 18.6 *Legionella*-Amoeba Interactions 241
- 18.7 Risk Factors 241
- 18.8 Detection/Diagnostic Testing 241
- 18.9 Symptoms 242
- 18.10 Long-Term Effects and Co-morbidities 243
- 18.11 Prevention 243
- 18.12 Pharmacology 244
- 18.13 Treatments in Development 245
- 18.14 New Technologies 246
- 18.15 Conclusion 248
- References 249

19 Babesiosis: An Emerging Global Threat 253

Komal Parmar and Jayvadan K. Patel

- 19.1 Introduction 253
- 19.2 World-Wide Babesiosis Human Infection 253
- 19.2.1 Americas 253
- 19.2.2 Europe 255
- 19.2.3 Asia, Africa and Australia 255
- 19.3 Life Cycle and Transmission 255
- 19.4 Clinical Features, Pathogenesis, and Diagnosis of Babesiosis 256
- 19.5 Management of Babesiosis 256
- 19.6 Conclusion 257
- References 257

20 Epidemiology and Current Trends in Malaria 261

Priya Patel, Arti Bagada, and Nasir Vadia

- 20.1 History of Malaria 261
- 20.1.1 Malaria and First World War 262
- 20.2 Types of Malaria 262
- 20.2.1 *Plasmodium vivax* (P.v) 262
- 20.2.2 *Plasmodium ovale* (P.o) 263
- 20.2.3 *Plasmodium falciparum* (P.f) 263
- 20.2.4 *Plasmodium malariae* (P.m) 263
- 20.2.5 Malaria and Plasmodium Biology 263
- 20.3 Worldwide Trend of Malaria (Geographical and Country)/The Spatial Epidemiology of Malaria Globally 264

20.3.1	WHO Response	265
20.3.2	High Burden to High Impact Approach	265
20.3.3	Current Malaria Burden in India	267
20.4	History of Malaria Control by Various Authorities/Agencies	267
20.4.1	History of Malaria Control	267
20.5	Diagnosis and Treatment	270
20.5.1	Microscopic Methods	271
20.5.2	Rapid Diagnostic Methodology (RDM) Adopted on Immunochromatography	271
20.5.3	Enzyme-Linked Immunosorbent Assay	271
20.5.4	Flow Cytometry	272
20.5.5	Advanced Molecular Technique	272
20.6	Prevention and Elimination of Malaria	272
20.7	Vaccine for Malaria and Current Trends of Malaria Treatment	273
20.8	Challenges for National Governments	275
20.9	Malaria Eradication Programme	276
20.9.1	Pillar 1. Ensure that Everyone Has Access to Treatment, Diagnosis, and Prevention for Malaria	277
20.9.2	Pillar 2. Intensify Efforts to Eradicate the Disease and Make the World Malaria-Free	277
20.9.3	Pillar 3. Establish Malaria Surveillance as a Focal Point of Treatment	277
20.9.4	Supporting Element 1. Increasing Research and Utilizing Innovation	277
20.9.5	Supporting Element 2. Enhancing the Favorable Environment	277
20.10	Conclusion	278
	References	278
21	Cryptosporidiosis: Recent Advances in Diagnostics and Management	283
	<i>Subhasundar Maji, Moitreyee Chattopadhyay, Debankini Dasgupta, Ananya Chanda, and Sandipan Dasgupta</i>	
21.1	Introduction	283
21.2	Epidemiology	284
21.3	What Is Cryptosporidium?	284
21.4	Mechanism of Cryptosporidium Infection	286
21.5	Diagnostic Methods	287
21.5.1	Acid-Fast Staining	288
21.5.2	Polymerase Chain Reaction	288
21.5.3	Immunofluorescence Assay	288
21.5.4	Enzyme-Linked Immunosorbent Assay	288
21.5.5	Loop-Mediated Isothermal Amplification	288
21.5.6	Microscopy with Infrared Staining	288
21.6	Management	288
21.7	Prevention and Control	291
21.8	Future Perspectives	293
21.9	Conclusion	294
	References	294
22	Leishmaniasis: Current Trends in Microbiology and Pharmacology	297
	<i>Ismaila Adams, Awo A. Kwapong, Eugene Boafo, Elizabeth Twum, and Seth K. Amponsah</i>	
22.1	Introduction	297
22.1.1	Global Epidemiology and Burden of Disease	297
22.1.2	Transmission and Vector Biology	298
22.2	Leishmania Species and Clinical Manifestations	298
22.2.1	Overview of <i>Leishmania</i> Species Causing Human Infection	298
22.2.2	Cutaneous Leishmaniasis: Clinical Presentation and Pathogenesis	299
22.2.3	Visceral Leishmaniasis: Clinical Presentation and Pathogenesis	299
22.3	Microbiology of Leishmania	299

22.3.1	Life Cycle and Stages	299
22.3.2	Molecular Biology and Genomics of <i>Leishmania</i>	300
22.3.3	Host–Parasite Interactions and Immune Response	301
22.4	Diagnosis of Leishmaniasis	301
22.4.1	Diagnostic Methods	301
22.4.1.1	Microscopy	302
22.4.1.2	Culture	302
22.4.1.3	Molecular Methods	302
22.4.1.4	ELISA	302
22.4.1.5	Immunochromatographic RDT	302
22.4.1.6	Immunoblotting	302
22.4.1.7	Direct Agglutination Test (DAT)	302
22.4.1.8	Leishmanin Skin Test (LST)	303
22.5	Drug Therapy for Leishmaniasis	303
22.5.1	First-Line Drugs and Their Mechanism of Action	303
22.5.1.1	Sodium Stibogluconate (Pentostam) and Meglumine Antimoniate (Glucantime)	303
22.5.1.2	Amphotericin B	303
22.5.1.3	Miltefosine	303
22.5.1.4	Paromomycin	303
22.5.2	Challenges and Limitations of Drug Therapy in Leishmaniasis	304
22.6	Drug Resistance in <i>Leishmania</i>	304
22.6.1	Genotypic Markers	304
22.6.1.1	Single Nucleotide Polymorphisms (SNPs)	304
22.6.1.2	Copy Number Variations (CNVs)	304
22.6.1.3	Gene Expression Profiling	305
22.6.2	Phenotypic Markers	305
22.6.2.1	<i>In Vitro</i> Drug Sensitivity Assays	305
22.6.3	Surveillance Methods	305
22.6.3.1	Field Monitoring	305
22.6.3.2	Molecular Surveillance	305
22.6.3.3	Global Collaboration and Databases	305
22.7	Strategies to Overcome Drug Resistance in <i>Leishmania</i>	305
22.7.1	Combination Therapy	305
22.7.2	Optimized Treatment Regimens	306
22.7.3	Development of New Drugs	306
22.7.4	Drug Combination Screening	306
22.7.5	Drug Delivery Optimization	306
22.7.6	Molecular Surveillance and Monitoring	306
22.7.7	Combination of Drug Therapy with Immunomodulation	306
22.7.8	Education and Awareness	306
22.8	New Developments in Antileishmanial Drugs	306
22.8.1	Enzymes and Metabolic Pathways	307
22.8.1.1	Folate Metabolism	307
22.8.1.2	Sterol Biosynthesis	307
22.8.1.3	Proteases	307
22.8.2	Cell Signaling Pathways	307
22.8.3	Transporters	307
22.8.4	DNA Topoisomerases	307
22.8.5	High-Throughput Screening and Repurposing	307
22.8.6	Nanotechnology and Drug Delivery Systems	307
22.9	Repurposing Existing Drugs	308
22.9.1	Drug Screening	308

22.9.2	Mechanism of Action	308
22.9.3	Synergistic Combinations	308
22.9.4	Safety and Pharmacokinetics	308
22.9.5	Clinical Trials	308
22.9.6	Accessibility and Affordability	308
22.10	Vector Control and Leishmaniasis Prevention	309
22.10.1	Environmental and Personal Protection Measures	309
22.10.2	Public Health Interventions	309
22.10.3	Future Perspectives and Challenges	309
22.11	Conclusion	309
	References	310

23 Recent Trends in Toxoplasmosis Diagnosis and Management 314

Mehul Chorawala, Nirjari Kothari, Aayushi Shah, Aanshi Pandya, Ishika Shah, and Bhupendra G. Prajapati

23.1	Introduction	314
23.1.1	Epidemiology	315
23.1.2	Life Cycle and Pathophysiology	315
23.1.3	Clinical Presentation	317
23.1.4	Current Diagnostic Tests for Toxoplasmosis	318
23.1.4.1	Microscopic Diagnosis	318
23.1.4.2	Serological Assays	318
23.1.4.3	Imaging Techniques	319
23.1.4.4	Molecular Methods	319
23.2	Recent Advances in Diagnosis	319
23.2.1	Novel Enhanced Dot Blot Immunoassay That Uses Colorimetric Bioassay for <i>T. gondii</i> Detection	319
23.2.2	A Fluorescent Immunosensor with Chitosan-ZnO-Nanoparticles	319
23.2.3	YKL-40 as a Novel Diagnostic Biomarker in Toxoplasmosis	320
23.2.4	Advances in Serological Methods Based on Recombinant Antigen of <i>T. gondii</i>	320
23.2.5	Advances in Serological Methods Based on Chimeric Antigens and Multiepitope Peptides of <i>T. gondii</i>	320
23.2.6	Advanced Molecular Technique	320
23.3	Current Management of Toxoplasmosis	321
23.3.1	Congenital Toxoplasmosis (CT)	321
23.3.1.1	Prenatal Treatment	323
23.3.1.2	Postnatal Treatment	323
23.3.2	Immunocompromised Patients	323
23.4	Need for Novel Treatment	324
23.5	Novel or Repurposed Therapeutic Molecules as Anti-Toxoplasma Activity	324
23.5.1	Searching for Compounds with Effects on Specific Parasitic Targets	325
23.5.2	Identifying Promising Compounds or Repurposing Potential Drugs Active Against Other Pathogens	326
23.5.3	Immunotherapeutic Arsenal Against Toxoplasmosis	328
23.6	Conclusion and Outlook	329
	Acknowledgment	329
	References	330

24 Recent Trends in Neurocysticercosis Diagnosis and Management 337

Sachin P. Bhatt, Avani N. Joshi, and Bhupendra G. Prajapati

	Abbreviations	337
24.1	Introduction	337
24.1.1	Life Cycle, Biology, and Transmission	338
24.1.2	Etiopathogenesis	339
24.1.3	Symptoms and Characteristics of Cysticerci	340
24.1.4	Epidemiology	340

24.1.5	Risk Factors for Acquiring Neurocysticercosis	340
24.1.6	Diagnosis of NCC	340
24.1.7	Neuroimaging	341
24.1.7.1	Parenchymal NCC	341
24.1.7.2	Subarachnoid NCC	341
24.1.7.3	Ventricular NCC	341
24.1.7.4	Spinal cord NCC	341
24.2	Immunologic Diagnosis	341
24.2.1	Neuroimaging	341
24.2.2	Muscle and Cranium X-Rays	342
24.2.3	Immunologic Diagnosis	342
24.2.4	Prognosis	343
24.2.5	Diagnostic Criteria and Degrees of Diagnostic Certainty for Neurocysticercosis	343
24.2.6	Limitation and Prospects for Improvement in Neurocysticercosis	344
24.3	Management Approaches by Neurocysticercosis Form	344
24.3.1	Management of Neurocysticercosis	344
24.3.2	Role of Antiparasitic Drugs	344
24.3.3	Complications of Anti-Parasitic Drugs	345
24.3.4	Role of Corticosteroids	345
24.3.5	Role of Anti-Epileptic's Drugs	346
24.3.6	Surgical Management for Neurocysticercosis	346
24.3.7	Issues and Challenges for Surgery of Neurocysticercosis	347
24.4	Conclusion	347
	References	348

25 Trichinosis: History and Current Trends 351

Moitreyee Chattopadhyay, Sandipan Dasgupta, Ananya Chanda, Subhasundar Maji, and Shwetlana Bandyopadhyay

25.1	Background	351
25.2	Historical Reports of Trichinosis Infection	351
25.3	The Discovery of Trichinosis	352
25.4	Major Outbreaks of Trichinosis	353
25.4.1	Germany	354
25.4.2	Poland	355
25.4.3	Russia	355
25.4.4	Outbreaks in Other European Countries	355
25.4.5	Africa	355
25.4.6	Asia and Pacific Region	356
25.4.7	North and South America	356
25.5	Trichinosis Episodes in Animals	356
25.5.1	Pigs	357
25.5.2	Horses	357
25.5.3	Wild boars	357
25.5.4	Dog	357
25.5.5	Bear	358
25.5.6	Marine mammals	358
25.5.7	Other animals	358
25.6	The Nematode: <i>Trichinella</i> sp.	358
25.7	Life Cycle of Trichinosis	359
25.7.1	Symptoms	360
25.7.2	Diagnosis	361
25.7.3	Management and Treatment with Medicines	362
25.8	Control of <i>Trichinella</i> Infection in Humans	363

25.9	Current Trend in Trichinella Epidemiology	363
25.10	Conclusion	364
	References	365

26 Schistosomiasis: Recent Clinical Reports and Management 368

Emmanuel K. Ofori and Akua O. Forson

26.1	Introduction	368
26.1.1	Acute Schistosomiasis	369
26.1.2	Established-Active-Infection	369
26.1.3	Late Chronic Infection	370
26.1.4	Immunology and Host–Parasite Interactions	370
26.1.5	Intestinal Schistosomiasis	370
26.1.6	Hepato-Splenic Schistosomiasis	370
26.1.7	Urogenital Schistosomiasis	370
26.2	Parasitology Diagnosis	371
26.3	Biomarkers: Screening, Detection of Worm Antigens and Specific Antibodies	371
26.4	Radiology	372
26.5	Management	372
26.5.1	Praziquantel	372
26.5.2	Limitations of Praziquantel	373
26.5.3	Artemisinin and its Derivatives	373
26.5.4	Adjuvants	373
26.5.5	New Anti-Schistosomal Drugs	374
26.5.6	Vaccines	374
26.6	Conclusion	374
	References	374

27 Granulomatous Amebic Encephalitis: Evolutionary Dynamics, Advances in Diagnostics and Therapeutic Interventions 378

Lucy Mohapatra, Alok S. Tripathi, Bhupendra G. Prajapati, Alka, Deepak Mishra, Mohammad Yasir, and Rahul K. Maurya

27.1	Introduction	378
27.2	Epidemiology for Granulomatous Amebic Encephalitis	379
27.3	Pathogenesis of Granulomatous Amebic Encephalitis	379
27.3.1	<i>Acanthamoeba Species</i> Intricated GAE	379
27.3.2	<i>Balamuthia mandrillaris</i> Intricated GAE	380
27.3.3	<i>Naegleria fowleri</i> Intricated GAE	382
27.3.4	Immune Responses and GAE	382
27.3.4.1	Tissue Inhibitors of MMPs (TIMPs) and Matrix Metalloproteinases (MMPs)	382
27.3.4.2	Neurotrophins: Neurotrophin-4 (NT-4) and Brain-Derived Neurotrophic Factor (BDNF)	382
27.3.5	Histopathological Changes	382
27.4	Evolutionary Dynamics Involved in Granulomatous Amebic Encephalitis	383
27.4.1	Evolution Regarding Genotypes of Pathogens in Granulomatous Amebic Encephalitis	383
27.4.2	<i>Acanthamoeba</i> -Endosymbionts Relationship	384
27.4.3	Evolutionary Dynamics Related to Lesion Inside Host	384
27.5	Diagnosis for Granulomatous Amebic Encephalitis	385
27.5.1	Traditional Method for Diagnosis	385
27.5.1.1	Microscopy	385
27.5.1.2	Cell Culture	385
27.5.2	Advances in Diagnosis of Granulomatous Amoebic Encephalitis	386
27.5.2.1	Molecular Method of Diagnosis	386
27.5.2.2	Neuroimaging	386

27.5.2.3	Serology	386
27.5.2.4	Histopathology	386
27.6	Advances in Therapeutic Interventions for Granulomatous Amebic Encephalitis	387
27.6.1	Treatment Therapy Used for GAE	387
27.6.2	Advances in the Treatment for Granulomatous Amebic Encephalitis	389
27.6.2.1	Gold-Conjugated Curcumin	389
27.6.2.2	Alkylphosphocholines (APC)	389
27.6.2.3	New Combination Approach	389
27.7	Conclusion	389
	References	389

28 Epidemiology and Current Treatment Trends in “*Thelaziasis*” 396

Rihana B. Patnool, Badrud D. Mohammad, Vishwas H. Nagendra, Bhupendra G. Prajapati, Muhasina K. Muhamadkazim, and Sivasankaran Ponnusankar

28.1	Introduction	396
28.2	Causative Agents	397
28.2.1	<i>Thelazia anolabiata</i>	397
28.2.2	<i>Thelazia bubalis</i>	397
28.2.3	<i>Thelazia callipaeda</i>	397
28.2.4	<i>Thelazia californiensis</i>	398
28.2.5	<i>Thelazia erschowi</i>	398
28.2.6	<i>Thelazia gulosa</i>	398
28.2.7	<i>Thelazia lacrymalis</i>	399
28.2.8	<i>Thelazia leesei</i>	399
28.2.9	<i>Thelazia rhodesii</i>	399
28.2.10	<i>Thelazia skrjabini</i>	399
28.3	Morphology	399
28.3.1	Morphology of <i>Thelazia gulosa</i>	400
28.3.2	Morphology of <i>Thelazia californiensis</i>	400
28.3.3	Morphology of <i>Thelazia rhodesii</i>	400
28.3.4	Morphology of <i>Thelazia skrjabini</i>	400
28.3.5	Morphology of <i>Thelazia lacrymalis</i>	402
28.4	Mode of Transmission	402
28.5	Hosts and Vectors	403
28.5.1	<i>Thelazia</i> 's Relationship to Their Specific Hosts	405
28.5.2	<i>Thelazia</i> 's Relationship to Their Definitive Hosts	405
28.6	Life Cycle of <i>Thelazia</i> Species	405
28.7	Molecular Acumens of <i>Thelaziasis</i> Species	406
28.8	Geographical Distribution	406
28.9	Clinical Presentations of <i>Thelaziasis</i>	407
28.10	Diagnosis of <i>Thelaziasis</i>	407
28.11	Treatment Options for <i>Thelaziasis</i>	407
28.12	Precautionary Measures	408
28.13	Preventive Measures for <i>Thelaziasis</i>	408
28.14	Recent Trends in <i>Thelaziasis</i> Control	409
28.15	Conclusion	409
	References	409

29 Trypanosomiasis: Current Trends in Microbiology and Pharmacology 411

Verner N. Orish

29.1	Introduction	411
29.2	History	412

29.3	Parasite	413
29.3.1	Classification of Trypanosomes	413
29.3.2	<i>Trypanosoma brucei</i> Specie	413
29.3.3	Tsetse Fly – Genus Glossina	414
29.3.3.1	Classification	414
29.3.3.2	Reproduction	415
29.3.3.3	Feeding Habit	415
29.3.3.4	Survival Strategies	416
29.4	Epidemiology of Human African Trypanosomiasis (HAT)	416
29.4.1	Transmission Dynamics	416
29.4.2	Burden of HAT in Endemic Areas	417
29.4.3	Impact on Children and Women	417
29.4.4	Burden of HAT in Non-Endemic Areas	417
29.5	Life Cycle of Trypanosoma	417
29.6	Other Mechanisms of Transmission	418
29.6.1	Congenital Transmission	418
29.6.2	Sexual Transmission	418
29.6.3	Extremely Rare Transmission Route	419
29.7	Pathogenesis of HAT	419
29.7.1	Trypomastigotes Induced Inflammation in the Skin	419
29.7.2	Host-Trypomastigotes Immune Interactions in the Blood and Lymphatics	419
29.7.3	Central Nervous System Injury	420
29.8	Clinical Manifestations	420
29.8.1	Trypanosomal Chancre	420
29.8.2	Early Stage	420
29.8.3	Late Stage	420
29.9	Diagnosis	420
29.9.1	Serology	421
29.9.2	Microscopy	421
29.9.3	Molecular Diagnosis	421
29.10	Treatment	421
29.10.1	Pentamidine Isethionate	421
29.10.2	Suramin	422
29.10.3	Melarsoprol	422
29.10.4	Eflornithine	422
29.10.5	Nifurtimox	422
29.11	Control and Prevention	423
29.11.1	Vector Control	423
29.11.2	Identifying and Treatment of Cases	423
29.11.3	Other Control Methods	423
29.12	Challenges of Control and Prevention	424
29.13	Conclusion	424
	References	424
30	Emerging and Re-Emerging Infectious Diseases of the Decade: Current Challenges and Future Directions	428
	<i>Seth K. Amponsah, Ranjita Shegokar, and Yashwant V. Pathak</i>	
30.1	Introduction	428
30.2	Factors Leading to the Emergence and Re-Emergence of Infectious Diseases	429
30.3	Current Challenges of Emerging and Re-Emerging Infectious Diseases	430
30.4	Strategies/Possible Interventions	431
30.4.1	Strengthening Surveillance and Rapid Response Mechanisms	431

30.4.2	Conforming to International Health Regulations	432
30.4.3	Building Capacity in Epidemiology	432
30.4.4	Strengthening of Laboratory and Networks	432
30.4.5	Research and Development	432
30.4.6	Information Sharing and Partnerships	433
30.5	Future Directions	433
30.6	Conclusion	434
	References	434

Index	438
--------------	------------

List of Contributors

Abdullah Abdelkawi

Taneja College of Pharmacy
University of South Florida
Tampa, FL
United States

Ismaila Adams

Department of Medical Pharmacology
University of Ghana Medical School
Accra
Ghana

Ofosua Adi-Dako

Department of Pharmaceutics and Microbiology
School of Pharmacy
University of Ghana
Accra
Ghana

Selorme Adukpo

Department of Pharmaceutics and Microbiology
School of Pharmacy
University of Ghana
Accra
Ghana

Alka

Amity Institute of Pharmacy, Lucknow
Amity University Uttar Pradesh
Noida, Uttar Pradesh
India

Seth K. Amponsah

Department of Medical Pharmacology
University of Ghana Medical School
Accra
Ghana

Abigail Aning

Department of Clinical Pathology
Noguchi Memorial Institute for Medical Research
University of Ghana
Accra
Ghana

Orhan E. Arslan

Department of Cellular Biology and Pharmacology
Florida International University Herbert Wertheim
College of Medicine
Miami, FL
United States

Arti Bagada

Department of Pharmaceutical Sciences
Faculty of Health Sciences
Saurashtra University
Rajkot, Gujarat
India

Shwetlana Bandyopadhyay

MGM College of Pharmacy
Chiraura, Patna
India

Praful D. Bharadia

Department of Pharmaceutics
L. M. College of Pharmacy
Ahmedabad, Gujarat
India

Sachin P. Bhatt

Gyanmanjari Pharmacy College
Gujarat Technological University
Bhavnagar, Gujarat
India

Eugene Boafo

Department of Medical Pharmacology
University of Ghana Medical School
Accra
Ghana

Chinmoyee Borah

Department of Pharmaceutical Sciences, Faculty of
Science and Engineering
Dibrugarh University
Dibrugarh, Assam
India

Kwasi A. Bugyei

Department of Medical Pharmacology
University of Ghana Medical School
Accra
Ghana

Ananya Chanda

Department of Pharmaceutical Technology
School of Medical Sciences
ADAMAS University
Kolkata, West Bengal
India

Chandrakanta

Department of Pharmaceutical Sciences
Faculty of Technology
Sir J. C. Bose Technical
Campus Bhimtal, Kumaun University Nainital
Nainital, Uttarakhand
India

Moitreyee Chattopadhyay

Department of Pharmaceutical Technology
Maulana Abul Kalam Azad University of Technology
Kolkata, West Bengal
India

Neha Chintapally

University of South Florida Morsani College of
Medicine
Tampa, FL
United States

Mehul Chorawala

Department of Pharmacology and Pharmacy Practice
L. M. College of Pharmacy, Gujarat University
Ahmedabad, Gujarat
India

Ankit Choudhary

Department of Pharmaceutical Sciences
Faculty of Science and Engineering
Dibrugarh University
Dibrugarh, Assam
India

Carina Copley

College of Agriculture and Life Sciences
The University of Florida
Gainesville, FL
United States

Jeannez Daniel

University of South Florida Morsani College of Medicine
Tampa, FL
United States

Aparoop Das

Department of Pharmaceutical Sciences
Dibrugarh University
Dibrugarh, Assam
India

Debankini Dasgupta

Department of Pharmacology
MGM College of Pharmacy
Patna, Bihar
India

Sandipan Dasgupta

Department of Pharmaceutical Technology
Maulana Abul Kalam Azad University of Technology
Kolkata, West Bengal
India

Akua O. Forson

Department of Medical Laboratory Sciences, School of
Biomedical and Allied Health Sciences
University of Ghana
Accra
Ghana

Mainak Ghosh

Department of Pharmaceutical Sciences
Faculty of Science and Engineering
Dibrugarh University
Dibrugarh, Assam
India

Urvashee Gogoi

Department of Pharmaceutical Sciences
Dibrugarh University
Dibrugarh, Assam
India

Bismarck A. Hottor

Department of Anatomy
University of Ghana Medical School
Accra
Ghana

Avani N. Joshi

Gyanmanjari Pharmacy College, Gujarat
Technological University
Bhavnagar, Gujarat
India

Bibhuti B. Kakoti

Department of Pharmaceutical Sciences, Faculty of
Science and Engineering
Dibrugarh University
Dibrugarh, Assam
India

Avinash D. Khadela

Department of Pharmacology
L. M. College of Pharmacy
Ahmedabad, Gujarat
India

Nirjari Kothari

Department of Pharmacology and Pharmacy Practice
L. M. College of Pharmacy, Gujarat University
Ahmedabad, Gujarat
India

Awo A. Kwapong

Department of Pharmaceutics and Microbiology, School
of Pharmacy
University of Ghana
Accra
Ghana

Monali Lahiri

Department of Pharmaceutical Sciences, Faculty
of Science and Engineering
Dibrugarh University
Dibrugarh, Assam
India

Anjali Mahapatra

University of South Florida Morsani College of Medicine
Tampa, FL
United States

Subhasundar Maji

Department of Pharmaceutical Technology
Maulana Abul Kalam Azad University of Technology
Kolkata, West Bengal
India

Rahul K. Maurya

Amity Institute of Pharmacy, Lucknow
Amity University Uttar Pradesh
Noida, Uttar Pradesh
India

Deepak Mishra

Amity Institute of Pharmacy, Lucknow
Amity University Uttar Pradesh
Noida, Uttar Pradesh
India

Badrud D. Mohammad

Department of Pharmaceutical Chemistry
GRT Institute of Pharmaceutical Education
and Research
Tirutanni, Tamil Nadu
India

Lucy Mohapatra

Amity Institute of Pharmacy, Lucknow
Amity University Uttar Pradesh
Noida, Uttar Pradesh
India

Muhasina K. Muhamadkazim

Department of Pharmacognosy
JSS College of Pharmacy
JSS Academy of Higher Education & Research
Ooty, The Nilgiris, Tamil Nadu
India

Vishwas H. Nagendra

Department of Pharmacy Practice
JSS College of Pharmacy
JSS Academy of Higher Education & Research
Ooty, Tamil Nadu
India

Meera Nagpal

University of South Florida Morsani College of
Medicine
Tampa, FL
United States

Lawandashisha Nongrang

Department of Pharmaceutical Sciences, Faculty
of Science and Engineering
Dibrugarh University
Dibrugarh, Assam
India

Lynn Nguyen

University of South Florida Morsani College of Medicine
Tampa, FL
United States

Eric N. Y. Nyarko

Department of Chemical Pathology
University of Ghana Medical School
Accra
Ghana

Emmanuel K. Ofori

Department of Chemical Pathology
University of Ghana Medical School
Accra
Ghana

Verner N. Orish

Department of Microbiology and Immunology
School of Medicine
University of Health and Allied Sciences
Ho
Ghana

Vaishnavi M. Oza

Department of Pharmaceutics
L. M. College of Pharmacy
Ahmedabad, Gujarat
India

Aanshi Pandya

Department of Pharmacology and Pharmacy Practice
L. M. College of Pharmacy, Gujarat University
Ahmedabad, Gujarat
India

Sambit K. Parida

Seth Vishambhar Nath Institute of Pharmacy
Barabanki, Uttar Pradesh
India

Rihana B. Patnool

Department of Pharmacy Practice
JSS College of Pharmacy
JSS Academy of Higher Education & Research
Ooty, Tamil Nadu
India

Komal Parmar

Department of Pharmacy, ROFEL
Shri G.M. Bilakhia College of Pharmacy
Vapi, Gujarat
India

Anita Patel

R & D Department
Samrajya Aromatics Pvt. Ltd.
Gandhinagar, Gujarat
India

Dhara Patel

Pioneer Pharmacy College
Vadodara, Gujarat
India

Geeta Patel

Shree S K Patel College of Pharmaceutical
Education and Research
Ganpat University
Kherva, Gujarat
India

Grishma Patel

Pioneer Pharmacy College
Vadodara, Gujarat
India

Jayvadan K. Patel

Formulation and Development Aavis Pharmaceuticals
Hoschton, GA
United States
Aavis Pharmaceuticals, Hoschton, Georgia, USA
and
Faculty of Pharmacy, Sankalchand Patel University
Visnagar, Gujarat, India

Kshama Patel

Judy Genshaft Honors College
The University of South Florida
Tampa, FL
United States

Manish P. Patel

Department of Pharmaceutics
L. M. College of Pharmacy
Ahmedabad, Gujarat
India

Nisarg Patel

Department of Pharmacognosy
APMC College of Pharmaceutical
Education and Research
Himatnagar, Gujarat
India

Priya Patel

Department of Pharmaceutical Sciences
Faculty of Health Sciences
Saurashtra University
Rajkot, Gujarat
India